sábado, 27 de octubre de 2012

National Guideline Clearinghouse | (1) Gonococcal infections. In: Sexually transmitted diseases treatment guidelines, 2010. (2) Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections.

full-text ►
National Guideline Clearinghouse | (1) Gonococcal infections. In: Sexually transmitted diseases treatment guidelines, 2010. (2) Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections.

Guideline Title

(1) Gonococcal infections. In: Sexually transmitted diseases treatment guidelines, 2010. (2) Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections.

Bibliographic Source(s)

Centers for Disease Control and Prevention (CDC). Gonococcal infections. In: Sexually transmitted diseases treatment guidelines, 2010 [Erratum appears in MMWR Recomm Rep. 2011 Jan 14;60(1):18]. MMWR Recomm Rep 2010 Dec 17;59(RR-12):49-55.

Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012 Aug 10;61:590-4. [11 references] PubMed External Web Site Policy

Guideline Status

This is the current release of the guideline.

MMWR Morb Mortal Wkly Rep. 2012 Aug 10;61(31):590-4.

Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections.

Centers for Disease Control and Prevention (CDC).

Abstract

Gonorrhea is a major cause of serious reproductive complications in women and can facilitate human immunodeficiency virus (HIV) transmission. Effective treatment is a cornerstone of U.S. gonorrhea control efforts, but treatment of gonorrhea has been complicated by the ability of Neisseria gonorrhoeae to develop antimicrobial resistance. This report, using data from CDC's Gonococcal Isolate Surveillance Project (GISP), describes laboratory evidence of declining cefixime susceptibility among urethral N. gonorrhoeae isolates collected in the United States during 2006-2011 and updates CDC's current recommendations for treatment of gonorrhea. Based on GISP data, CDC recommends combination therapy with ceftriaxone 250 mg intramuscularly and either azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days as the most reliably effective treatment for uncomplicated gonorrhea. CDC no longer recommends cefixime at any dose as a first-line regimen for treatment of gonococcal infections. If cefixime is used as an alternative agent, then the patient should return in 1 week for a test-of-cure at the site of infection.